Allam Lamyaa, Bekouti Jean Timnou, Gabra Mohamed Diaa, Shogade Tolulope Taiwo, El-Hariri Hazem Mohamed, Seddik Ait Messaoudene Mohamed, Kahled Bouasria, Vezi Brian, Jabeur Mariem, Soulemane Pessinaba, Sonou Arnaud, Alison Michael Rory, Houchinne Lemoné, Adjougoulta Koboy Allah-Amine, Roberto José, Stephane Kouame Koffi, Diakité Adama, Stéphane Ikama Méo, Jeewoth Avinash, Gandye Yona, Bonny Aimé
Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Interventional Cardiology Center of Douala, Douala, Cameroon.
J Cardiovasc Electrophysiol. 2025 Sep;36(9):2117-2131. doi: 10.1111/jce.16523. Epub 2025 Jan 7.
Data are scarce regarding Wolf-Parkinson White Syndrome (WPW) syndrome and asymptomatic pre-excitation in Africa. This study tried to understand the current approaches utilized in Africa for the diagnosis and management of both symptomatic and asymptomatic ventricular pre-excitation.
The current prospective study was conducted in 20 centers located in 17 countries spanning all areas of Africa. Participants included had ventricular pre-excitation patterns. The data collected included symptoms, locations of accessory pathways (AP) and tachyarrhythmia, risk stratification, as well as acute and long-term management. In addition, we assessed the clinical effectiveness of the centers and the impact of socioeconomic and health metrics on these treatment approaches.
Among 541 participants, 93% were diagnosed with WPW syndrome, with orthodromic atrioventricular reciprocating tachycardia (AVRT) being the most prevalent arrhythmia, affecting 55% of the cases. Approximately 30% of patients in Africa, except for the southern region, received intravenous amiodarone as the first-choice drug for orthodromic AVRT while adenosine was the drug of choice in the Southern region. Electrical cardioversion was the first-line treatment for pre-excited atrial fibrillation and antidromic AVRT across all of Africa. Radiofrequency ablation (RF) was the first long-term therapy option for 88% of patients in all African regions, unlike western and central Africa where it was implemented for less than 30% of patients (p < 0.001). The rates of RF success, long-term recurrence, and complications were 93%, 4.1%, and 3.8%, respectively.
There are significant variations between African regions in terms of diagnostic workup, accessory pathway localizations, and volume of invasive treatment. Countries in Northern and Southern Africa are more advanced than other African countries in terms of modern management strategy. Additional government investments are necessary to enhance diagnostic likelihood and curative treatments as well as to reduce the gap between different regions in Africa.
关于非洲地区预激综合征(WPW)和无症状预激的数据较为匮乏。本研究旨在了解非洲地区目前用于诊断和管理有症状及无症状心室预激的方法。
当前的前瞻性研究在非洲各地17个国家的20个中心开展。纳入的参与者具有心室预激模式。收集的数据包括症状、旁路(AP)位置和快速性心律失常、风险分层以及急性和长期管理情况。此外,我们评估了各中心的临床疗效以及社会经济和健康指标对这些治疗方法的影响。
在541名参与者中,93%被诊断为WPW综合征,其中房室折返性心动过速(AVRT)是最常见的心律失常,占病例的55%。除南部地区外,非洲约30%的患者接受静脉注射胺碘酮作为顺向性AVRT的首选药物,而南部地区则首选腺苷。电复律是整个非洲地区预激性房颤和逆向性AVRT的一线治疗方法。射频消融(RF)是所有非洲地区88%患者的首选长期治疗方案,这与西非和中非地区不到30%的患者接受该治疗形成对比(p < 0.001)。RF的成功率、长期复发率和并发症发生率分别为93%、4.1%和3.8%。
非洲各地区在诊断检查、旁路定位和侵入性治疗量方面存在显著差异。在现代管理策略方面,北非和南非的国家比其他非洲国家更为先进。需要政府增加投资,以提高诊断可能性和治疗效果,并缩小非洲不同地区之间的差距。